|
|
|
|
|
|
|
|
|
|
|
06.11.26 - 05:48
|
Inovio′s Voceryq receives FDA accelerated approval for RRP (PBR)
|
|
|
Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and
The post Inovio's Voceryq receives FDA accelerated approval for RRP appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
05.11.26 - 22:03
|
INOVIO Announces Proposed Public Offering of its Common Stock (PR Newswire)
|
|
|
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that......
|
|
|
|
|
02.11.26 - 22:03
|
INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
|
|
|
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.09.26 - 22:09
|
INOVIO to Participate in Upcoming Investor Conferences (PR Newswire)
|
|
|
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in......
|
|